Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome.

THE WOODLANDS, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1031, an internally-developed small molecule compound for gastrointestinal disorders such as irritable bowel syndrome. Following FDA review, Lexicon intends to initiate a Phase 1 clinical trial of LX1031 in healthy volunteers to assess the compound's safety, tolerability and pharmacokinetics. In preclinical studies, LX1031 has demonstrated the ability to reduce peripheral serotonin, a neurotransmitter that is known to play a major role in gastrointestinal function. LX1031 works locally in the gastrointestinal tract with little systemic exposure and has exhibited an excellent safety profile in preclinical studies.

"We…